Department of Pediatric Oncology/Hematology, Helios Clinics Schwerin, Wismarsche Straße 393-397, 19049 Schwerin, Germany.
Medical School Hamburg (MSH), University of Applied Sciences and Medical University, Am Kaiserkai 1, 20457 Hamburg, Germany.
Int J Mol Sci. 2023 Jan 4;24(2):952. doi: 10.3390/ijms24020952.
Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Moreover, HB324 showed synergistic activity with various established anticancer drugs and overcame resistance in several cell lines, such as neuroblastoma cells. In conclusion, HB324 showed promising potential as a novel anticancer agent in vitro, suggesting further investigations on this and other preclinical ruthenium drug candidates.
钌（II）配合物与 N-杂环卡宾（NHC）配体作为新型化疗药物引起了人们的关注。HB324 复合物作为一种诱导凋亡的化合物在耐药细胞系中得到了深入研究。HB324 通过线粒体途径诱导细胞凋亡。特别值得注意的是，上调了 Harakiri 抗性蛋白，该蛋白抑制了抗凋亡和死亡抑制蛋白 Bcl-2（B 细胞淋巴瘤 2）和 BCL-xL（B 细胞淋巴瘤-特大）。此外，HB324 与各种已建立的抗癌药物具有协同作用，并克服了几种细胞系中的耐药性，如神经母细胞瘤细胞。总之，HB324 在体外显示出作为新型抗癌药物的有前景的潜力，这表明需要对该药物和其他临床前钌候选药物进行进一步研究。
